Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,958.00
Bid: 1,963.00
Ask: 1,965.00
Change: -36.00 (-1.81%)
Spread: 2.00 (0.102%)
Open: 2,004.00
High: 2,004.00
Low: 1,958.00
Prev. Close: 1,994.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-Hikma in joint-venture to tap high-growth Ethiopian market

Wed, 18th Sep 2013 11:43

By Paul Sandle

LONDON, Sept 18 (Reuters) - Jordan's Hikma Pharmaceuticals has formed a joint venture with Sheikh Mohammed HusseinAl Amoudi's MIDROC Group to enter the Ethiopian healthcaremarket, where health spending is likely to more than double inthe next few years.

London-listed Hikma said the joint venture, HikmaCure, wouldcreate an Ethiopian operating company, build a localmanufacturing facility and would begin marketing anddistributing pharmaceutical products in Ethiopia.

"Ethiopia is still very underdeveloped in terms of thepharmaceutical market," Mazen Darwazah, executive vice chairmanand chief executive of Hikma's Middle East and North Africabusiness, said in an interview.

"It's a market that has huge potential for growth. We areexpecting an increase in expenditure on healthcare: today is$400 million but we are expecting it in the next couple of yearsto go up to $1 billion."

Ethiopia, Africa's second most populous nation, has seen adecade of double-digit growth, and it has leapfroggedneighbouring Kenya to become sub-Saharan Africa's fifth biggesteconomy.

The country's population of 91 million people is served byjust 5,000 doctors, compared with 40,000 doctors in Egypt for 85million people, Hikma said.

Hikma and MIDROC will provide up to $22.3 million each tothe joint venture, Hikma said.

Hikma manufactures and sells branded pharmaceuticals inMiddle Eastern and North African markets including Algeria,Saudi Arabia and Sudan. It also has a U.S. focused genericsbusiness and an injectables unit.

Jeddah-based MEDROC, which has operations in sectorsincluding petroleum, agriculture, engineering and construction,is a major investor in Ethiopia, where it has based its Africanoperations. The group's chairman, Sheikh Mohammed Al-Amoudi, isof Ethiopian-Yemeni heritage, according to his website, and heis the largest foreign investor in Ethiopia.

Analyst James Vane-Tempest at Jefferies said the jointventure was a positive for the company and it added furthercredibility to its expansion strategy.

"Ethiopia is one of the largest markets in the region and inour view offers strong long-term growth potential," he said.

Shares in the group were up 0.9 percent at 1,036 pence by1016 GMT.

More News
9 Feb 2022 09:48

LONDON BROKER RATINGS: Barclays downgrades Chemring and boohoo

LONDON BROKER RATINGS: Barclays downgrades Chemring and boohoo

Read more
3 Feb 2022 09:12

Hikma completes acquisition of Teligent's Canadian assets

Hikma completes acquisition of Teligent's Canadian assets

Read more
17 Jan 2022 09:01

TOP NEWS: Hikma Pharmaceutical acquires Teligent for USD45.8 million

TOP NEWS: Hikma Pharmaceutical acquires Teligent for USD45.8 million

Read more
17 Jan 2022 09:00

TOP NEWS: Hikma Pharmaceutical acquires Teligent for USD45.8 million

TOP NEWS: Hikma Pharmaceutical acquires Teligent for USD45.8 million

Read more
17 Jan 2022 07:49

LONDON MARKET PRE-OPEN: Unilever sees good fit in GSK Consumer Health

LONDON MARKET PRE-OPEN: Unilever sees good fit in GSK Consumer Health

Read more
17 Jan 2022 07:08

Hikma buys Teligent Canadian assets for $47.75m

(Sharecast News) - Hikma Pharmaceuticals on Monday said it had agreed to buy the Canadian assets of Teligent for $45.75m after the US firm filed for Chapter 11 bankruptcy last year.

Read more
10 Jan 2022 07:44

LONDON MARKET PRE-OPEN: Plus500 hails 2021 and mulls new share buyback

LONDON MARKET PRE-OPEN: Plus500 hails 2021 and mulls new share buyback

Read more
10 Jan 2022 07:24

Hikma launches new US injectables unit

(Sharecast News) - Hikma Pharmaceuticals on Monday said it was expanding its injectables business with the launch of a new outsourced sterile compounding business in the US.

Read more
21 Dec 2021 15:55

Arecor flags milestone payment from Hikma in first half of next year

(Sharecast News) - Biopharmaceutical company Arecor Therapeutics updated the market on its ongoing exclusive agreement with Hikma Pharmaceuticals to co-develop a new, ready-to-use injectable medicine on Tuesday.

Read more
9 Dec 2021 09:25

Hikma adds two biosimilars to portfolio with Gedeon Richter agreement

Hikma adds two biosimilars to portfolio with Gedeon Richter agreement

Read more
9 Dec 2021 08:32

Hikma strikes exclusive license agreement with Richter for denosumab

(Sharecast News) - Drugmaker Hikma Pharmaceuticals has entered into an exclusive license agreement with Gedeon Richter to commercialise the latter's denosumab products in the US.

Read more
4 Nov 2021 09:03

TOP NEWS: Hikma confirms 2021 guidance amid strong performance

TOP NEWS: Hikma confirms 2021 guidance amid strong performance

Read more
4 Nov 2021 07:58

Hikma reports solid trading in year to date

(Sharecast News) - Hikma Pharmaceuticals reiterated full-year guidance as the company reported solid trading across its business.

Read more
1 Nov 2021 13:52

Citi sees room for upside surprise on sales at Hikma Pharmaceuticals

(Sharecast News) - Analysts at Citi reiterated their 'buy' stance for shares of Hikma Pharmaceuticals ahead of the company's trading statement due out later in the same week.

Read more
28 Oct 2021 16:12

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.